DONNA

TapImmune Announces Commercialization Pathway For Its HER2neu Vaccine

November 5th, 2016 | Posted In: Research Updates

Closer to the Finish!  DONNA partner TapImmune announces the commercialization pathway for its HER2neu Vaccine and the initiation of company-sponsored Phase 2 Clinical Trials that will start early 2017. In a Phase I clinical trial on the four Class II antigens in HER2neu breast cancer patients performed at the Mayo Clinic, over 90 percent of patients developed a robust T-cell response against these antigens.

Leave a Reply

Be the First to Comment!

Notify of
wpDiscuz

Stay Posted

Stay Posted

Locals Rule

Locals Rule

YesWay

YesWay

Team Donna

Team Donna

Donna partners

The Donna Foundation

The Donna Foundation

Jeff Galloway

Jeff Galloway

Mayo Clinic

Mayo Clinic

Learn More

Learn More about 26.2 with Donna Partners